Management of Functional Pancreatic Neuroendocrine Neoplasms

[1]  H. Jacob,et al.  ENDOSCOPIC ULTRASOUND-GUIDED RADIOFREQUENCY ABLATION VERSUS SURGICAL RESECTION FOR TREATMENT OF PANCREATIC INSULINOMA. , 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  A. Larghi,et al.  Small nonfunctional pancreatic neuroendocrine neoplasms: Time for a step-up treatment approach? , 2022, Endoscopic ultrasound.

[3]  H. Kato,et al.  Endoscopic ablation therapy for the pancreatic neoplasms , 2022, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[4]  M. Falconi,et al.  How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery , 2022, Current Oncology Reports.

[5]  V. Mazzaferro,et al.  Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies , 2021, World journal of gastroenterology.

[6]  D. Laaksonen,et al.  Long-term morbidity and mortality in patients diagnosed with an insulinoma , 2021, European journal of endocrinology.

[7]  L. Moilanen,et al.  Characteristics and outcomes of the Finnish ectopic ACTH syndrome cohort , 2021, Endocrine.

[8]  Joseph M Pappachan,et al.  Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot , 2021, World journal of gastrointestinal surgery.

[9]  F. Panzuto,et al.  Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia , 2021, Expert opinion on drug safety.

[10]  R. Jensen,et al.  Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes , 2020, Expert opinion on pharmacotherapy.

[11]  A. Dohan,et al.  The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review , 2020, Journal of clinical medicine.

[12]  M. Falconi,et al.  Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. Ricci,et al.  The functioning side of the pancreas: a review on insulinomas , 2020, Journal of Endocrinological Investigation.

[14]  A. Tabarin,et al.  MANAGEMENT OF ENDOCRINE DISEASE: Cushing's syndrome due to ectopic ACTH secretion: an expert operational opinion. , 2020, European journal of endocrinology.

[15]  R. Jensen,et al.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies , 2019, Expert review of anticancer therapy.

[16]  S. Vege,et al.  Vasoactive Intestinal Peptide-Secreting Tumors: A Review. , 2019, Pancreas.

[17]  E. Pilozzi,et al.  Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center , 2019, Journal of clinical medicine.

[18]  L. Nieman,et al.  Advances in the medical treatment of Cushing's syndrome. , 2019, The lancet. Diabetes & endocrinology.

[19]  W. D. de Herder,et al.  Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors , 2018, The Journal of clinical endocrinology and metabolism.

[20]  J. Strosberg,et al.  Gastroenteropancreatic Neuroendocrine Tumors , 2018, CA: a cancer journal for clinicians.

[21]  R. Jensen,et al.  Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms , 2018, Neuroendocrinology.

[22]  K. Öberg.  Management of functional neuroendocrine tumors of the pancreas. , 2018, Gland surgery.

[23]  Shouhao Zhou,et al.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States , 2017, JAMA oncology.

[24]  M. Falconi,et al.  Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome. , 2017, The oncologist.

[25]  M. Falconi,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors , 2017, Neuroendocrinology.

[26]  M. Falconi,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours , 2017, Neuroendocrinology.

[27]  Joseph J Bennett,et al.  Clinical Presentation and Diagnosis of Pancreatic Neuroendocrine Tumors. , 2016, Surgical oncology clinics of North America.

[28]  R. Jensen,et al.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors , 2016, Neuroendocrinology.

[29]  J. Bilezikian,et al.  Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). , 2012, The Journal of clinical endocrinology and metabolism.

[30]  W. Burns,et al.  Neuroendocrine Pancreatic Tumors: Guidelines for Management and Update , 2012, Current Treatment Options in Oncology.

[31]  R. Jensen,et al.  ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes , 2011, Neuroendocrinology.

[32]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[33]  R. Jensen,et al.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. , 2010, Pancreas.

[34]  A. Faggiano,et al.  The biological characterization of neuroendocrine tumors: The role of neuroendocrine markers , 2008, Journal of endocrinological investigation.

[35]  H. Moch,et al.  Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. , 2008, Endocrine-related cancer.

[36]  R. Jensen,et al.  Serum Gastrin in Zollinger-Ellison Syndrome: I. Prospective Study of Fasting Serum Gastrin in 309 Patients From the National Institutes of Health and Comparison With 2229 Cases From the Literature , 2006, Medicine.

[37]  R. Naranjo,et al.  [Necrolytic migratory erythema associated with glucagonoma]. , 2005, Actas dermo-sifiliograficas.

[38]  K. Öberg.  Interferon in the Management of Neuroendocrine GEP-Tumors , 2000, Digestion.

[39]  F. Sundler,et al.  Localization of vasoactive intestinal polypeptide (VIP) to central and peripheral neurons. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Norton,et al.  Prospective Evaluation of Results of Reoperation in Zollinger-Ellison Syndrome , 2018, Annals of surgery.

[41]  J. Bilezikian,et al.  Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 ( MEN 1 ) , 2012 .

[42]  S. Lamberts,et al.  Dopamine receptor expression and function in corticotroph ectopic tumors. , 2007, The Journal of clinical endocrinology and metabolism.

[43]  K. Oberg.  Interferon in the management of neuroendocrine GEP-tumors: a review. , 2000, Digestion.